When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. But have you ever wondered about what other factors affect a stock's price? Stock prices are primarily based on seller supply and buyer demand. What Caused Ocular Therapeutix Inc Stock’s Price to Rise?
OTX PRICE FREE
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions Year to date, Ocular Therapeutix Inc’s stock is down 0.72%. Over the last year, Ocular Therapeutix Inc has hit prices as high as $7.32 and as low as $2.57. Ocular Therapeutix Inc’s ( OCUL) price is currently up 8.13% so far this month.ĭuring the month of June, Ocular Therapeutix Inc’s stock price has reached a high of $6.93 and a low of $6.26.
Ocular Therapeutix Inc Stock Price History
We recommend investors evaluate other financial metrics to understand its overall valuation. Unfortunately, Ocular Therapeutix Inc’s P/E ratio is not significant enough to use for stock price evaluation. Currently, there are 77.39 million shares of Ocular Therapeutix Inc stock available for purchase. Ocular Therapeutix Inc is up 7.79% from its previous closing price of $6.42.ĭuring the last market session, Ocular Therapeutix Inc’s stock traded between $6.26 and $6.47. Ocular Therapeutix Inc’s Stock Price as of Market CloseĪs of June 02, 2023, 4:00 PM CST, Ocular Therapeutix Inc’s stock price was $6.92. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips. Want to learn more about Ocular Therapeutix Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ocular Therapeutix Inc.
OTX PRICE TRIAL
Its earlier stage development assets include: axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy travoprost intracameral implant (OTX-TIC), is under Phase II clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension and dexamethasone intracanalicular insert (OTX-DED), for the short-term treatment of the signs and symptoms of dry eye disease and cyclosporine intracanalicular insert (OTX-CSI), for the chronic treatment of dry eye disease, both of which have completed Phase II clinical trials. Its first commercial drug product, DEXTENZA, is developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocular itching associated with allergic conjunctivitis. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Stock price momentum as measured by its relative strengthīefore we jump into Ocular Therapeutix Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.In this article, we go over a few key elements for understanding Ocular Therapeutix Inc’s stock price such as: A smart way to take the guesswork out of knowing when to buy or sell Ocular Therapeutix Inc’s stock is to have the right tools and resources as well as a clear monitoring process. One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.īut what if you had the insights to effectively evaluate a company like Ocular Therapeutix Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes.
0 kommentar(er)
